PYC Therapeutics Presents Promising VP-001 Clinical Trial Data for RP11 at APVRS 2024.

PYC Therapeutics (ASX: PYC), a clinical-stage biotechnology company, has announced the presentation of clinical trial data for its drug candidate VP-001 at the Asia Pacific Vitreo-Retina Society (APVRS) conference in Singapore on November 23, 2024. At the time of writing, VP-001 is being developed as the first treatment for Retinitis Pigmentosa type 11 (RP11), a rare childhood eye disease. Associate Professor Fred Chen of the Lions Eye Institute will present Phase 1/2 trial results, highlighting improvements in retinal sensitivity and Low Luminance Visual Acuity (LLVA) in treated patients compared to baseline and untreated eyes. VP-001 targets the genetic cause of RP11 by restoring PRPF31 protein levels.

Granted orphan drug and fast-track designations by the FDA, it marks a major breakthrough in tackling this AU$1 billion annual market opportunity. PYC is preparing for FDA engagement in 2025 to design a registrational trial anticipated to begin mid-year.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com